Organ Preservation Therapy Using Induction Plus Concurrent Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania Phase II Trial
Top Cited Papers
- 1 October 2002
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (19) , 3964-3971
- https://doi.org/10.1200/jco.2002.11.026
Abstract
PURPOSE: To determine the efficacy, feasibility, and toxicity of a new regimen for locally advanced oropharyngeal carcinoma. PATIENTS AND METHODS: Patients had technically resectable stage III/IV squamous cell carcinoma of the oropharynx, exclusive of T1-2N1. Induction chemotherapy consisted of carboplatin (area under the curve formula equal to 6) and paclitaxel 200 mg/m2 for two cycles, followed by re-evaluation. Patients with major response continued to definitive radiotherapy (70 Gy over 7 weeks) plus concurrent once-weekly paclitaxel (30 mg/m2/wk). Patients with advanced neck disease also underwent post–radiation therapy neck dissection and two more chemotherapy cycles. RESULTS: Fifty-three patients were enrolled. Median follow-up was 31 months (minimum follow-up for survivors was 18 months). The major response rate to induction chemotherapy was 89%; 90% of patients had a complete response after concurrent chemoradiation. Actuarial survival at 3 years was 70%, and 3-year event-free survival was 59%. The 3-year actuarial locoregional control was 82% and the 3-year actuarial rate of distant metastases was 19%. Organ preservation was achieved in 77% of all patients. One patient (2%) died during therapy. Late grade 3 toxicity occurred in 24% of patients, consisting mainly of chronic dysphagia/aspiration and/or radiation soft tissue ulceration. The treatment-related mortality rate was 4% (two patients died from respiratory failure). CONCLUSION: Response to induction chemotherapy as studied in this trial was not useful as a predictive marker for ultimate outcome or organ conservation. Overall, however, this regimen offers good disease control and survival for patients with locally advanced oropharyngeal carcinoma, comparable with other concurrent chemoradiation programs. Further study of similar protocols is indicated.Keywords
This publication has 45 references indexed in Scilit:
- Accelerated chemoradiation to 70.6 GY is more effective than accelerated radiation to 77.6 GY alone-two years results of a German multicentre randomized trialInternational Journal of Radiation Oncology*Biology*Physics, 2000
- A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary resultsHead & Neck, 1997
- Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III TrialJNCI Journal of the National Cancer Institute, 1996
- A review of neoadjuvant chemotherapy for head and neck cancer: Partially shrunken tumors may be both leaner and meanerInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Surgical management of squamous cell carcinoma of the base of the tongueThe American Journal of Surgery, 1993
- Carcinoma of the tonsillar fossa: A nonrandomized comparison of irradiation alone or combined with surgery: Long‐term resultsHead & Neck, 1991
- Response to chemotherapy as justification for modification of the therapeutic strategy for pharyngolaryngeal carcinomasHead & Neck, 1990
- Combined radiation therapy and surgery in the management of advanced head and neck cancer: Final report of study 73–03 of the radiation therapy oncology groupHead & Neck Surgery, 1987
- Failure at distant sites following multimodality treatment for advanced head and neck cancerHead & Neck Surgery, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958